CTLA4 and hypophysitis: According to a recent meta-analysis, the incidence of hypophysitis is <0.1% with anti-PD-L1 antibodies, 0.4% with anti-PD-1 antibodies, 3.2% with anti-CTLA-4 antibodies, and 6.4% with combination therapy [2].